The travel vaccines market in North America is expected to grow from US$ 1,276.32 million in 2021 to US$ 2,503.59 million by 2028; it is estimated to grow at a CAGR of 10.1% from 2021 to 2028.
Travelling and tourism have become an integral part of the human lifestyle. Travelling and tourism have not only added a change in the ongoing routine of people but have also offered opportunities to explore different cultures, traditions, spiritualism, rural and ethnic tourism, wellness and health holidays, and many more worldwide. Travelling outside the country requires immunization as a safety and precautionary measure to avoid spreading infections. Various countries have policies to protect their citizens from travel-associated infections. The above estimates suggest that travel and tourism will increase in the coming years. Furthermore, economic crises and demand for better job opportunities contributed to the increasing travel and tourism across the region. Thus, the increasing travel and tourism propel the demand for travel vaccines. Furthermore, economic crises and demand for better job opportunities have contributed to the increasing travel and tourism worldwide. Thus, the increasing travel and tourism propel the demand for travel vaccines.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America travel vaccines market. The North America travel vaccines market is expected to grow at a good CAGR during the forecast period.
North America Travel Vaccines Market Revenue and Forecast to 2028 (US$ Million)
North America Travel Vaccines Market Segmentation
North America travel vaccines market is segmented into product, application, and country. The North America travel vaccines market, by product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. In 2021, the others segment held the largest share of the market. By application, the North America travel vaccines market is segmented into domestic and outbound travel. In 2021, the outbound travel segment held the largest share of the market. Based on country, the North America travel vaccines market is segmented into the US, Canada, and Mexico. The US held the largest market share in 2021.
Abbott; Dynavax Technologies; Emergent BioSolutions Inc.; GlaxoSmithKline plc; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Sanofi; and Valneva SE are among the leading companies in the travel vaccines market in the region.
North America Travel Vaccines Market Strategic Insights
North America Travel Vaccines Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 1,276.32 Million |
| Market Size by 2028 | US$ 2,503.59 Million |
| CAGR (2021 - 2028) | 10.1% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product
|
|
Regions and Countries Covered
|
|
| North America | US, Canada, Mexico |
| Market leaders and key company profiles |
|
North America Travel Vaccines Market Country and Regional Insights
